Medicare begins covering GLP-1 obesity drugs for first time, capping patient cost at $50 a month

CMS's Medicare GLP-1 Bridge program launches July 1, giving an estimated 15-20 million eligible beneficiaries access to tirzepatide (Zepbound) and semaglutide (Wegovy) at a $50 monthly cap under a deal struck by the Trump administration with Novo Nordisk and Eli Lilly in late 2025

Summary

Medicare began covering GLP-1 obesity medications on July 1 for the first time in the programme's 60-year history, under a Centers for Medicare and Medicaid Services demonstration called the Medicare GLP-1 Bridge. Tirzepatide (Zepbound, Eli Lilly) and semaglutide (Wegovy, Novo Nordisk) are the initially approved drugs, with patients paying no more than $50 per month. The programme runs through December 2027. Eligibility requires a body mass index of 35 or above, or a BMI of 30 to 35 with at least one qualifying condition such as uncontrolled hypertension, prediabetes, prior heart attack, chronic kidney disease, or diastolic heart failure. CMS estimates 15 to 20 million Medicare beneficiaries qualify. The $50 price point follows a deal struck by the Trump administration with Eli Lilly and Novo Nordisk in November 2025 as part of broader drug-pricing negotiations.

Why it matters

Medicare Part D had explicitly excluded weight-loss drugs since its creation in 2003; lifting the exclusion via a demonstration programme, even temporarily, sets a precedent that will shape the permanent coverage debate after 2027. With 15 to 20 million potential patients, the programme could add tens of billions in annual revenue to Novo Nordisk and Eli Lilly while testing whether expanded access reduces downstream cardiovascular and diabetes costs for the federal budget.

the record · 1

CMS (Centers for Medicare & Medicaid Services)Jun 30, 2026 — CMS confirmed that Zepbound (tirzepatide, Eli Lilly) and Wegovy (semaglutide, Novo Nordisk) are the initially approved drugs under the Bridge, with the KwikPen formulation of Zepbound specifically listed. The agency said the program is a time-limited CMS Innovation Center demonstration and that participation requires beneficiaries to enroll through their existing Part D plan.

Regional takes · 2

▸ US business network; June 30 explainer on the July 1 launch covering eligibility, pricing, and market impact on Novo Nordisk and Eli Lilly

CNBC · United States · en · Jun 30, 2026 08:00Z

CNBC reported that Medicare's GLP-1 Bridge program begins July 1, offering $50-per-month access to approved obesity medications. The piece noted that Novo Nordisk and Eli Lilly shares were set to benefit, as the program could unlock 15 to 20 million new patients across Medicare's Part D. Eligibility requires a BMI of 35 or above, or a BMI of 30 to 35 combined with at least one qualifying comorbidity such as uncontrolled hypertension, prediabetes, or chronic kidney disease.

“Medicare obesity drug GLP-1 coverage starting July 1.”

Source ↗

▸ US network health desk; pre-launch explainer published June 29 covering coverage mechanics and patient eligibility

CNN Health · United States · en · Jun 29, 2026 14:00Z

CNN framed the July 1 launch as the first time in Medicare's 60-year history that the program has covered weight-loss drugs. The piece explained that CMS's GLP-1 Bridge demonstration runs through December 2027 and that qualifying patients must have a body mass index at or above 35 or a lower BMI with at least one cardiovascular or metabolic comorbidity. The administration struck the $50 price deal directly with Eli Lilly and Novo Nordisk in November 2025 as part of broader drug-pricing negotiations.

“Medicare will start covering weight-loss drugs on July 1 for the first time.”

Source ↗